Abstract
The increased numbers of activated eosinophils in the blood and tissues that typically accompany hypereosinophilic disorders result from a variety of mechanisms. Exciting advances in translating discoveries achieved from mouse models and molecular strategies to the clinic have led to a flurry of new therapeutics specifically designed to target eosinophil-associated diseases. So far, this form of hypothesis testing in humans in vivo through pharmacology generally has supported the paradigms generated in vitro and in animal models, raising hopes that a spectrum of novel therapies soon may become available to help those who have eosinophil-associated diseases.
Original language | English (US) |
---|---|
Pages (from-to) | 357-375 |
Number of pages | 19 |
Journal | Immunology and Allergy Clinics of North America |
Volume | 27 |
Issue number | 3 |
DOIs | |
State | Published - Aug 2007 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology